4.8 Article

Unstable Angina: Is It Time for a Requiem?

Journal

CIRCULATION
Volume 127, Issue 24, Pages 2452-2457

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIRCULATIONAHA.113.001258

Keywords

angina, unstable; troponin

Funding

  1. Accumetrics
  2. Amgen
  3. Athera
  4. AstraZeneca
  5. Beckman Coulter
  6. BG Medicine
  7. Bristol-Myers Squibb
  8. Buhlmann Diagnostics
  9. CV Therapeutics
  10. Daiichi Sankyo Co Ltd
  11. Eli Lilly and Co
  12. GlaxoSmithKline
  13. Integrated Therapeutics
  14. Johnson Johnson
  15. Merck and Co
  16. Merck-Schering Plow Joint Venture
  17. Nanosphere
  18. Novartis Pharmaceuticals
  19. Nuvelo
  20. Ortho-Clinical Diagnostics
  21. Pfizer
  22. Roche Diagnostics
  23. Sanofi-Aventis
  24. Sanofi-Synthelabo
  25. Schering-Plow
  26. Siemens
  27. Singulex
  28. Daiichi Sankyo
  29. Genzyme
  30. Amorcyte
  31. Medicines Company
  32. MC Communications
  33. Ikaria
  34. CardioRentis
  35. Sanofi Aventis
  36. Beckman-Coulter
  37. Critical Diagnostics
  38. Genentech
  39. Gilead
  40. Instrumentation Laboratories
  41. Merck
  42. Servier

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available